@article{JTD14426,
author = {Alyn H. Morice and Lorcan McGarvey and Ian D. Pavord and Bernard Higgins and Kian Fan Chung and Surinder S. Birring},
title = {Theobromine for the treatment of persistent cough: a randomised, multicentre, double-blind, placebo-controlled clinical trial},
journal = {Journal of Thoracic Disease},
volume = {9},
number = {7},
year = {2017},
keywords = {},
abstract = {Background: To investigate the effect of BC1036 on health-related quality of life (QOL) in subjects with persistent cough. The secondary objective was to investigate the effect of BC1036 on subjective cough severity.
Methods: This was a randomised, multicentre, double-blind, placebo-controlled, parallel-group study in 289 subjects with persistent cough. Subjects received BC1036 or placebo twice daily for 14 days. The primary endpoint comprised cough-related QOL assessed using the validated Leicester Cough Questionnaire (LCQ) at Day 14. Secondary endpoints comprised the LCQ scores at Day 7 and Day 28, cough severity VAS scores at each visit and pulmonary function tests.
Results: At baseline, mean total LCQ score in the BC1036 group was lower (i.e., worse QOL) than placebo (P},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/14426}
}